Oh What A Headache At Syntex
It's a good thing Syntex makes painkillers. On June 2, company execs got the bad news: An advisory committee to the Food & Drug Administration recommended that Syntex' flagship product, the popular arthritis drug Naprosyn, not be approved for over-the-counter use. Syntex stands to lose big in December, when Naprosyn, a billion-dollar drug, goes off patent. The company had teamed up with Procter & Gamble hoping to sell Naprosyn without a prescription, but the FDA committee had concerns over the lack of data demonstrating that the drug is safe in OTC doses. Given Syntex' nearly empty new-product pipeline, this setback sets it way back.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- The U.S. Drops Out of the Top 10 in Innovation Ranking
- Musk's New Pay Deal Could Make Him the World's Richest Man—If Tesla Succeeds
- Here’s What Trump’s Tariffs on U.S. Imports Are Doing to Markets
- Bitcoin May Split 50 Times in 2018 as Forking Craze Mounts
- Trump's Tariffs on Solar Mark Biggest Blow to Renewables Yet